Logo

News & Publications

Press Releases

December 09, 2013
Acetylon Pharmaceuticals Presents Preclinical Data for Selective HDAC1/2 Inhibitors for the Treatment of Sickle Cell Disease and β-Thalassemia at the American Society of Hematology Annual Meeting
December 09, 2013
Acetylon Pharmaceuticals Highlights Positive Interim Phase 1b Clinical Data of Ricolinostat (ACY-1215) in Multiple Myeloma at the American Society of Hematology Annual Meeting
December 09, 2013
Acetylon Pharmaceuticals Presents Data on the Potent Activity of Ricolinostat (ACY-1215) in Preclinical Models of Lymphoma at the American Society of Hematology Annual Meeting
July 29, 2013
Acetylon Pharmaceuticals and Celgene Corporation Announce an Exclusive Strategic Collaboration to Advance the Science of Epigenetics
June 20, 2013
Acetylon Announces Preclinical Data of ACY-1215 for the Treatment of Lymphoma Highlighted at 12th International Conference on Malignant Lymphoma (ICML)
June 17, 2013
Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215 for the Treatment of Multiple Myeloma
June 13, 2013
Acetylon Pharmaceuticals to Present Data Supporting ACY-1215 in Multiple Myeloma and Lymphoma at Upcoming Hematology Conferences
May 20, 2013
Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference
December 10, 2012
Preclinical Results for Acetylon Pharmaceuticals’ Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at ASH 2012
December 10, 2012
Clinical and Preclinical Results for Acetylon Pharmaceuticals’ ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology
November 20, 2012
Acetylon Pharmaceuticals' Selective HDAC Inhibitor Programs to be Featured at the 54th Annual Meeting of the American Society of Hematology
October 09, 2012
Acetylon to Participate on Financing Panel and Provide Corporate Update at BIO Investor Forum
September 10, 2012
Acetylon Pharmaceuticals to Participate in Upcoming Conferences
August 03, 2012
Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene's Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma
April 20, 2012
Acetylon Announces Issuance of a United States Patent with Composition of Matter Claims for Its Lead HDAC6 Inhibitor Drug Candidate Rocilinostat (ACY-1215)
February 09, 2012
Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation
December 12, 2011
Acetylon Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for Rocilinostat (ACY-1215) in Multiple Myeloma
December 12, 2011
Acetylon Announces Addition of Catherine A. Wheeler MD as Vice President Clinical Development
June 29, 2011
Acetylon Pharmaceuticals Announces Completion of $27 Million Series B Round of Private Investor Financing
May 11, 2011
The Leukemia & Lymphoma Society and Acetylon Pharmaceuticals Partner to Advance the Clinical Development of Acetylon's Rocilinostat (ACY-1215) Drug Candidate for Multiple Myeloma
April 25, 2011
Acetylon Pharmaceuticals Adds HDAC Biology, Inflammation and Neurodegeneration Experts to its Scientific Advisory Board
December 06, 2010
Acetylon Announces Publication of Preclinical Safety and Efficacy Results for Lead Drug Candidate Rocilinostat (ACY-1215) in Multiple Myeloma
November 11, 2010
Acetylon Pharmaceuticals Inc. Awarded Two Therapeutic Discovery Project Grants
March 08, 2010
Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute
March 08, 2010
Harvard University and Dana-Farber Cancer Institute Grant Acetylon Exclusive License to Breakthrough Discovery Platform for Next Generation HDAC Inhibitors
January 08, 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and John van Duzer VP Chemistry and Manufacturing
August 07, 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis